In the latest Cochrane Review
, recently published in the BMJ
, researchers say there is no solid evidence to support claims that neuraminidase inhibitors (Tamiflu or Relenza) reduce the symptoms of flu.
Commenting on these findings, Dr. David Tovey, editor in chief at Cochrane, says: "Initially thought to reduce hospitalizations and serious complications from influenza, the review highlights that Tamiflu is not proven to do this, and it also seems to lead to harmful effects that were not fully reported in the original publications. This shows the importance of ensuring that trial data are transparent and accessible."
For more editorial discussion go here